Campaign Encourages E&C Lawmakers to Focus on Big Pharma’s Anti-Competitive
Tactics and Egregious Pricing Practices That Keep Americans Paying Highest Drug
Prices in the World





 



CSRxP: BIG PHARMA IS DRIVING HEALTH CARE INFLATION; CONGRESS MUST HOLD BIG
PHARMA ACCOUNTABLE TO DELIVER AFFORDABILITY FOR AMERICAN PEOPLE

Campaign Encourages E&C Lawmakers to Focus on Big Pharma’s Anti-Competitive
Tactics and Egregious Pricing Practices That Keep Americans Paying Highest Drug
Prices in the World



Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released
the following statement ahead of a Wednesday hearing titled “Lowering Health
Care Costs for All Americans: An Examination of the Prescription Drug Supply
Chain” in the U.S. House Committee on Energy and Commerce Subcommittee on
Health.



“Prescription drug prices are the single largest contributor to rising health
care costs, placing increasing financial pressure on patients and their
families, employers and taxpayers,” said CSRxP executive director Lauren
Aronson. “Big Pharma’s anti-competitive tactics, including patent thickets,
product hopping and evergreening, enable drug manufacturers to set high drug
prices, and repeatedly hike prices, while blocking more affordable
alternatives, like generics and biosimilars, from reaching the market. To
deliver affordable health care and medications for American people, lawmakers
must hold Big Pharma accountable for the egregious anti-competitive tactics and
price-gouging practices that keep drug prices high.”



As Congress considers solutions to address prescription drug affordability,
CSRxP urges lawmakers to advance bipartisan, market-based legislation that
targets Big Pharma’s anti-competitive tactics and lowers drug prices for
patients.



Congress should pass bipartisan, market-based solutions
<[link removed]> to lower drug prices by holding Big Pharma
accountable, including:

* Biosimilar Red Tape Elimination Act (R. 5526
<[link removed]> and
S.1954 <[link removed]>)
* The Drug-price Transparency for Consumers (DTC) Act (R. 3789
<[link removed]> and S.229
<[link removed]>)
* The Skinny Labels, Big Savings Act (R. 6485
<[link removed]> and S.43
<[link removed]>)
* The Eliminating Thickets to Increase Competition (ETHIC) Act (R. 3269
<[link removed]> and
S.2276 <[link removed]>)
* The Interagency Patent Coordination and Improvement Act (R. 4570
<[link removed]>
andS.1097
<[link removed]>
)
* The Affordable Prescriptions for Patients Act (1041
<[link removed]>)
* The Preserve Access to Affordable Generics and Biosimilars Act (1096
<[link removed]>)
* The Drug Competition Enhancement Act (1040
<[link removed]>)
* The Stop STALLING Act (1095
<[link removed]>
)
* Medication Affordability and Patent Integrity Act (2658
<[link removed]>)
* Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
(2620 <[link removed]>)
Read CSRxP’s full comment letter to the Energy and Commerce Committee on the
hearingHERE
<[link removed]>
.



Read more on how Big Pharma is responsible for high prescription drug prices
and health care inflation in the United StatesHERE
<[link removed]>
.



Read more on solutions to lower prescription drug prices by holding Big Pharma
accountableHERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>